CLOVIS is next on the FDA Calendarfor PDUFA review, then Prometic. CLOVIS is trading below average daily volume and some reports suggest short interest is building... My point: Just because you have something in the works with the FDA doesn't mean your stock is going to skyrocket. Hopefully an FDA PDUFA approval for PLI Plasminogen will boost our share price higher. IT SHOULD but the volume is so low (for at least the last 6 months). Perhaps interest on the TSX has run it's course. We really do have to get on the NASDAQ sooner than later. GLTA!